Sign In
17 Feb 2011 07:00
GW Pharmaceuticals PLC("GW Pharmaceuticals" or the "Company")
Sativex® granted reimbursement in Spain
Porton Down, UK, 17 February 2011: GW Pharmaceuticals (AIM: GWP) is pleased to announce that Sativex® has been granted national reimbursement in Spain from the Spanish Ministry of Health.
Sativex® is expected to be launched shortly in Spain by GW's marketing partner Almirall, S.A. (ALM). The full text of the release from Almirall follows below.
Sativex® granted reimbursement in Spain, for the treatment of spasticityin multiple sclerosis
This is the first specific treatment for spasticity associated with multiple sclerosis (MS) which will be available in the Spanish hospital pharmacies shortly
Barcelona, February 16th, 2011: Almirall, S.A. (ALM) announces that the Spanish Ministry of Health granted the reimbursement of Sativex® in Spain, as confirmed by the Spanish Ministry of Health. It is the first treatment specifically designed for patients with MS-related spasticity who have not responded to other treatments. Sativex® is administered as an oral spray, enabling flexible dosage, which is particularly appropriate given the variable nature of spasticity and MS itself.
The approval of Sativex® in additional EU member states is expected in 2011.
It is estimated that there are around 40,000 people suffering from MS in Spain1 of whom around 75% suffer from spasticity, a painful and debilitating disorder that causes stiffness in muscles, painful cramps and sudden uncontrolled movements in limbs (spasms) that increase tiredness and reduced mobility. Even daily activities such as unscrewing a bottle top or getting out of bed can become difficult, affecting the patients' quality of life and state of mind.2
Sativex® is an endocannabinoid system modulator made up principally of two active ingredients -THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol)-, and developed by GW Pharmaceuticals (UK). The Phase III programme for Sativex® in cancer pain started late 2010.
Almirall, S.A. has the marketing rights in Europe (except the UK).
This is the first prescription medicine approved in Spain derived from cannabis and will be available with full reimbursement to MS patients in hospitals.
For more information:
GW Pharmaceuticals plc Dr Geoffrey Guy, Chairman Justin Gover, Managing Director | Today: +44 20 7831 3113 Thereafter: + 44 1980557000 |
Peel Hunt Limited (Nominated Adviser) James Steel Vijay Barathan | +44 (0) 20 7418 8900 |
Financial Dynamics Ben Atwell / John Dineen | + 44 (0) 20 7831 3113 |
Notes to editors
Sativex®
Sativex® was developed by GW Pharmaceuticals plc, United Kingdom as a specific response to unmet needs of the population suffering from MS. The medicine is manufactured in the United Kingdom and Almirall holds marketing rights in Europe (except United Kingdom).
Sativex® is indicated as an add-on treatment for patients with moderate to serious spasticity due to multiple sclerosis (MS) who have not adequately benefitted from other anti-spasticity medications and who have demonstrated a clinically significant improvement in symptoms related to spasticity during an initial treatment testing period.2
Spasticity
Spasticity or muscle stiffness is one of the most common symptoms of MS, affecting around 80% of patients with MS. It has a negative impact on their daily lives, as muscle stiffness reduces their ability to perform daily activities such as walking, keeping upright, movement in general or bowel function (bladder), as well as causing sleep problems.
If spasticity is not properly controlled, these patients' quality of life is greatly affected. They are forced to modify or abandon certain activities and often require help from a family member or carer.
In the five most important markets in the EU there are around 500,000 people suffering from MS and 40,000 cases of the disease have been diagnosed in Spain.1
About Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing. Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatological conditions. Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.
For further information please visit the website at: www.almirall.com
About GW Pharmaceuticals
GW Pharmaceuticals plc (AIM:GWP) was founded in 1998 and is listed on the AiM, a market of the London Stock Exchange. Operating under licence from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular MS and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com
Bibliography
1 Atlas of MS database (http://www.atlasofms.org/)- MSIF. Latest update 2008.
2 Multiple Sclerosis International Federation. Spasticity in MS. MS in focus. Issue 12. 2008. Available at: http://www.msif.org/docs/MSinFocusIssue12EN.pdf (latest access: 11/08/2010).
Follow the stocks
